Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy and reduce our operating expenses following the termination of the KRX-0401 license agreement; our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by the Company; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Colo. , June 1 Encision Inc. (OTC ... technology that is emerging as a standard of care in ... purchasing agreement with HealthTrust Purchasing Group, LP ("HealthTrust"), effective ... are "Laparoscopic Safety Instruments – Active Electrode Monitoring Laparoscopy". , ...
... DURECT Corporation (Nasdaq: DRRX ) announced today that James E. Brown , ... Conference on Thursday, June 10 at 10:30 a.m. Eastern Time . ... .   , , , ... , , ...
Cached Medicine Technology:Encision and HealthTrust Purchasing Group Sign Purchasing Agreement 2DURECT to Present at the Jefferies Global Life Sciences Conference 2
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ ... resolve,” said Steve Young of Ew Publishing; “I’ve had ... that is more intense.” , “It should be a ... migraines, that medical research is pointing to some relief ... , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses and ... announced evening cocktail dresses . As a matter ... are very popular among worldwide customers. Now, all its ... to 65 percent off). , All UWDress.com’s employees ... outfits for the global clients. The company is famous ...
(Date:9/20/2014)... GA (PRWEB) September 20, 2014 David ... 20, 2014. The first poster looked at the clinical ... cardiac cycle for calculating diastolic function. In conjunction with ... end-stage renal disease and normal LVEF by echo (>50%). ... stress protocol, and standard SPECT. Emory Toolbox 4.0 ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... Electronic devices of the future could be smaller, faster, ... discovery by researchers at the Department of Energy,s Oak ... published in Science , involves a method to ... decades have held tremendous promise but have eluded experimental ...
... 17 HealthTronics, Inc. ("HealthTronics") (Nasdaq: HTRN ... ) announced today that HealthTronics has commenced an exchange ... common stock pursuant to their previously-announced definitive agreement dated ... of the exchange offer, Endocare stockholders who validly tender ...
... Inclusion of General Surgeons, Otolaryngologists and , Ophthalmologists ... The American College of Surgeons (ACS) supports legislation ... Zack Space (D-Ohio), which includes the participation of general ... Loan Repayment Program called the Access to Frontline Health ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that it ... June 24 in Boston, Massachusetts. , , A live webcast ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... of the webcast will be available for 30 days after the ...
... ... Center, the most comprehensive program in Orange County. Hoag Voice and Swallowing Center provides ... , ... CA (Vocus) June 17, 2009 -- Hoag Hospital announces the grand opening of ...
... Health-privacy advocates and patient-choice supporters will discuss implications of federal ... on Thursday, June 18 at 9:00 am. Health-policy experts will ... HEALTH-PRIVACY RIGHTS: Which bills will make sure Americans are not ... and track them from cradle to grave and that citizens ...
Cached Medicine News:Health News:ORNL finding could help electronics industry enter new phase 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 3Health News:American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
Medicine Products: